Performance

Tesamorelin for Visceral Fat and Body Recomposition: A Research Guide for Personal Trainers and Performance Coaches

Tesamorelin is the only GHRH analogue with FDA approval — for HIV-associated lipodystrophy — backed by Phase III RCT evidence showing 15–17% visceral fat reduction at 26 weeks. This intermediate guide for personal trainers covers the mechanism, Phase III evidence, non-HIV population research, comparison with CJC-1295 and HGH, and what the evidence means for body recomposition research in clients over 40.

Performance

CJC-1295 / Ipamorelin Stack: An Intermediate Research Guide for Bodybuilders and Performance Athletes

CJC-1295 and Ipamorelin are two complementary growth hormone secretagogues that work through different receptor pathways — GHRH and GHS-R — to produce synergistic GH pulse amplification. This intermediate guide explores their mechanisms, clinical pharmacokinetics, combination rationale, and what the evidence says about GH, IGF-1, and body composition research.

Shopping Cart
Chat with us!
Scroll to Top